Tessa Therapeutics Completes US$126 Million Financing Led by Polaris Partners
Proceeds to fund clinical development of Tessa’s autologous (TT11) and allogeneic (TT11X) cell therapy programs Amy Schulman and Darren Carroll from Polaris Partners have joined Tessa’s Board of Directors Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the......